Cesar Perez, MD

home / authors / cesar-perez-md

Articles

head and neck cancer

Improving the Management of HNSCC: Next Steps

Victoria Meucci Villaflor, MD;Cesar Perez, MD
November 16th 2021

Dr Cesar Perez reacts to the utilization of next-generation sequencing in head and neck squamous cell carcinoma and highlights future areas of study.

head and neck cancer

HRAS Mutations in Head and Neck Cancer

Victoria Meucci Villaflor, MD;Cesar Perez, MD
October 29th 2021

The significance of studying strategies that target HRAS mutations in head and neck squamous cell carcinoma.

head and neck cancer

Precision Medicine in Head and Neck Cancer

Victoria Meucci Villaflor, MD;Cesar Perez, MD
October 22nd 2021

Key takeaways from a paper that evaluated the efficacy of tipifarnib in recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.

head and neck cancer

Presentation: Tipifarnib in HNSCC With HRAS Mutations

Victoria Meucci Villaflor, MD;Cesar Perez, MD
October 15th 2021

Drs Cesar Perez and Victoria Meucci Villaflor review “Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations” by Ho AL, et al.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
patients on the trial expected acupuncture to reduce cancer-related symptoms like pain and fatigue (4.2 ± 0.8), allow them to cope with their cancer (3.9 ± 1.0), decrease emotional distress (3.9 ± 1.0), and prevent future health problems (3.3 ± 1.1).
Published: April 11th 2025 | Updated: April 23rd 2025
Social Determinants of Health Affect Acupuncture Expectancy in Breast Cancer